# US 2023/0399373 A1 · Molecular designs of glucose-responsive and glucose-cleavable insulin analogues

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0399373 A1
- Document ID: US20230399373A1
- Status: Published application
- Kind: A1
- Application number: 18/033,229
- Filed: 2021-10-22
- Published: 2023-12-14
- Earliest claimed: 2020-10-22
- Assignees: The Trustees of Indiana University
- Applicants: The Trustees of Indiana University
- Inventors: Michael A. WEISS; Balamurugan DHAYALAN; Mark A. JAROSINSKI
- Web page: https://patentgrep.com/patent/US20230399373A1

## CPC

- C07K 14/62: Insulins
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A two-chain insulin analogue is provided containing (a) a B chain modified by a C-terminal diol element such that one hydroxyl group substitutes for the C-terminal carboxylate function in combination with (b) a glucose-binding element attached to the A chain at or near its N terminus. Compositions comprising such insulin analogs are used in methods of treating a patient with diabetes mellitus.

## Claims

### Claim 1

An insulin analogue consisting of an A chain modified by a glucose-binding element at or near its N terminus and a variant B chain comprising a diol group at the C terminus of the B chain such that the polypeptide chain ends with a hydroxyl group rather than with a carboxylate group.

### Claim 2 (depends on 1)

An insulin analogue of claim 1 wherein the A chain contains a substitution at position A8 that enhances affinity of the insulin analogue for the insulin receptor, optionally wherein the substitution at position A8 is histidine.

### Claim 3 (depends on 1)

An insulin analogue of claim 1 wherein the A chain contains a substitution at position A8 or position A14 that enhances thermodynamic stability of the insulin analogue for the insulin receptor, optionally wherein the substitution at position A8 or A14 is independently selected from the group consisting of HisA8, LysAB, ArgA8, and GluA8.

### Claim 4 (depends on 1)

An insulin analogue of claim 1 wherein the A chain contains a substitution at position A21 that protects the insulin analogue from chemical degradation.

### Claim 5 (depends on 2)

An insulin analogue of claim 2 wherein said diol group at the C terminus of the B chain is an aliphatic (1, 2) diol.

### Claim 6 (depends on 2)

An insulin analogue of claim 2 wherein said diol group at the C terminus of the B chain is an aliphatic (1, 3) diol.

### Claim 7 (depends on 1)

An insulin analogue of claim 1 further comprising a modified amino acid at a position 1, 2, 3, or 4 residues N-terminal to the C-terminal amino acid, wherein said modified amino acid is an L or D amino acid comprising a side-chain diol.

### Claim 8 (depends on 7)

An insulin analogue of claim 7 wherein the modified amino acid is thiol-containing L or D amino acid.

### Claim 9 (depends on 2)

An insulin analogue of claim 2 further comprising an L Dopa at position B26 or an L or D Dopa located at 1-3 residues N-terminal to the C-terminal amino acid.

### Claim 10 (depends on 1)

An insulin analogue of claim 1 where said B chain is a truncated B chain lacking residue B30, residues B29-B30, residues B28-B30, residues B27-B30 or residues B26-B30, with a diol group located at the C terminus of the truncated B chain.

### Claim 11 (depends on 1)

An insulin analogue of claim 1 where said B chain is extended by one or two amino acids with a diol group located at the C terminus of the extended B chain.

### Claim 12 (depends on 1)

An insulin analogue of claim 1 wherein the B chain is a polypeptide selected from the group consisting of
(SEQ ID NO: 1)
FVKQHLCGSHLVEALYLVCGERGFFYTEKX30,
(SEQ ID NO: 2)
FVNQHLCGSHLVEALYLVCGERGFFYTDKX30,
(SEQ ID NO: 3)
FVNQHLCGSHLVEALYLVCGERGFFYTKPX30,
(SEQ ID NO: 4)
FVNQHLCGSHLVEALYLVCGERGFFYTPKX30
(SEQ ID NO: 5)
FVNQHLCGSHLVEALYLVCGERGFFYTKX30,
(SEQ ID NO: 6)
FVNQHLCGSHLVEALYLVCGERGFFYTPX29X30,
(SEQ ID NO: 7)
FVNQHLCGSHLVEALYLVCGERGFFYTPX30
(SEQ ID NO: 8)
FVNQHLCGSHLVEALYLVCGERGFFYTX29X30
(SEQ ID NO: 9)
FVNQHLCGSHLVEALYLVCGERGFFYTX30
and
(SEQ ID NO: 10)
FVNQHLCGSHLVEALYLVCGERGFFYX30,
wherein
X29 is ornithine; and
X30 is a diol bearing amino acid derivative, optionally threoninol.

### Claim 13 (depends on 1)

An insulin analogue of claim 1 wherein the B chain is a polypeptide selected from the group consisting of
(SEQ ID NO: 37)
FVNQHLCGSHLVEALYLVCGERGFF[Sar][APD],
(SEQ ID NO: 38)
FVNQHLCGSHLVEALYLVCGERGFF[dA][APD],
and
(SEQ ID NO: 39)
FVNQHLCGSHLVEALYLVCGERGFFYG[APD],
wherein APD is 3-amino-1,2-propandiol.

### Claim 14 (depends on 1)

An insulin analogue of claim 1 wherein the B chain is a polypeptide selected from the group consisting of
(SEQ ID NO: 11)
FVNQHLCGSHLVEALYLVCGERGFFYTDKX31X30,
(SEQ ID NO: 12)
FVNQHLCGSHLVEALYLVCGERGFFYTKPX31X30,
(SEQ ID NO: 13)
FVNQHLCGSHLVEALYLVCGERGFFYTPKX31X30,
(SEQ ID NO: 14)
FVNQHLCGSHLVEALYLVCGERGFFYTDKX31X32X30,
(SEQ ID NO: 15)
FVNQHLCGSHLVEALYLVCGERGFFYTKPX31X32X30
and
(SEQ ID NO: 16)
FVNQHLCGSHLVEALYLVCGERGFFYTPKX31X32X30,
wherein
X31 and X32 are independently any amino acid; and
X30 is a diol bearing amino acid derivative, optionally threoninol.

### Claim 15 (depends on 12, 13)

An insulin analogue of claim 12 or 13 wherein the A chain is a polypeptide selected from the group consisting of
(SEQ ID NO: 17)
R-GIVEQCCTSICSLYQLENYCN;
and
(SEQ ID NO: 18)
R-GIVEQCCHSICSLYQLENYCN,
wherein
R is

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method of preparing an analogue of any one of claims 1-15 by means of trypsin-mediated semi-synthesis wherein (a) any optional A-chain modification (i.e., by a monomeric glucose-binding moiety) is introduced within a des-octapeptide[B23-B30] fragment of insulin or insulin analogue and (b) the diol-containing B-chain modification is introduced within a synthetic peptide of length 5-10 amino-acid residues whose N-terminal residue is Glycine and which upon modification contains no tryptic cleavage site.

### Claim 17 (depends on 16)

The method of claim 16 wherein the des-octapeptide[B23-B30] fragment of insulin or an insulin analogue is obtained by trypsin digestion of a parent insulin or insulin analogue.

### Claim 18 (depends on 16)

A method of claim 16 wherein the des-octapeptide[B23-B30] fragment of insulin or insulin analogue is obtained by trypsin digestion of a single-chain polypeptide (such as proinsulin, a proinsulin analogue or a corresponding mini-proinsulin containing a foreshortened or absent C domain) as expressed in Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris or other microbial system for the recombinant expression of proteins.

### Claim 19 (depends on 16)

The method of claim 16 wherein the des-octapeptide[B23-B30] fragment of insulin or insulin analogue is obtained by trypsin digestion of single-chain polypeptide (such as proinsulin, a proinsulin analogue or a corresponding mini-proinsulin containing a foreshortened or absent C domain) as prepared by solid-phase chemical peptide synthesis, optionally including native fragment-ligation steps.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method of treating a diabetic patient comprising administering a physiologically effective amount of an insulin analogue of any one of claims 1-15, or a physiologically acceptable salt thereof to the patient.
